About Us

bonus 1a

Bonus Biogroup (TASE: BONS) is an advanced clinical-stage biotechnology company developing 'next-generation' therapies for a variety of indications in the regenerative medicine field. As pioneers in the industry, we leverage our extensive knowledge and expertise to establish a unique technological platform, which underpins the development of our leading products, BonoFill™ and MesenCure™.

Our Vision

Bonus Biogroup strives to Empower millions of patients to live healthier and longer lives through scientific leadership and excellence, technological innovation, and a patient-centric approach.


Our mission

We aim to develop and deliver safe, effective, and affordable tissue engineering and cell therapy products to address severe conditions representing multi-billion-dollar markets with limited treatment options.

Our mission

We aim to develop and deliver safe, effective, and affordable tissue engineering and cell therapy products to address severe conditions representing multi-billion-dollar markets with limited treatment options.



Bonus Biogroup founding year



Establishment of Haifa facility



First-in-human BonoFill™ clinical trial



Successful first-in-human demonstration



Launch of phase I/II BonoFill™ clinical trial



Granting primary patents



Launch of Phase I/II MesenCure clinical trial



Phase II clinical trial for treating severe COVID patients with MesenCure.



MesenCure global phase III trial and BonoFill™ phase II/III clinical trial

Combining a strong team with state-of-the-art infrastructure.

At the helm of Bonus Biogroup are our CEO, Dr. Shai Meretzki, a serial founder of multiple biotech companies, and our Executive Chairman, Yossi Rauch, formerly the Chief Economist and Manager of the Economics Department at Leumi PIA. Our leadership guides a strong team with expertise spanning R&D, GMP manufacturing, regulatory affairs, and clinical operations. Over 90% of our R&D personnel hold advanced degrees, and our management team—with 75% being Ph.D. holders—blends experience and academic and business rigor, consistently driving groundbreaking innovations.


In 2022, we established our base at the new Bonus Biogroup House in Haifa, Israel. This state-of-the-art facility is designed to comply with the GMP standards mandated by the FDA and EMA. It is dedicated to the R&D and manufacturing of our products, equipped to meet commercial demands. The Center houses two product-specific production halls and quality control labs and boasts Israel's most advanced R&D labs for cell therapy and tissue engineering.

Our journey: The Story of Bonus Biogroup

Established in 2008 by Dr. Shai Meretzki and a team of tissue engineering experts, Bonus Biogroup embarked on a mission to revolutionize regenerative medicine. The company has since developed a unique technological platform that enables the harvesting, growth, and professionalization of cells with exceptional therapeutic potential.

In 2013, Bonus Biogroup erected the world's first manufacturing center for live bones. This groundbreaking achievement paved the way for the initiation of the first-in-human Proof-of-Concept (PoC) study in 2014 with BonoFill™, the company's live human bone graft. BonoFill™ has since demonstrated safety and efficacy in dozens of patients, including those who had exhausted all other treatment options.

Between 2016 and 2017, the company launched two clinical trials using BonoFill to treat facial and critical-sized limb bone defects. These trials progressed into Phase II during 2017-18, after validating the product's safety. By 2023, enrollment in the facial study was completed, with an impressive 90% success rate reported in the interim. A Phase II study for treating critical limb bone defects is currently underway, with promising safety and efficacy results in reported cases. The company anticipates initiating advanced-phase clinical trials with BonoFill in the US.

MesenCure, another innovative product from Bonus Biogroup, was initially developed to address inflammation and tissue damage in severe COVID-19 patients. The product entered a first-in-human study in early 2021, and by 2022, a Phase II trial had concluded, demonstrating impressive clinical outcomes. Beyond its initial application, MesenCure has shown potential for treating ARDS from various causes and also exhibits promise in treating other conditions, such as lethal toxicities and tissue damage induced by chemotherapy, cytokine release syndrome from CAR-T immunotherapy, and other tissue inflammation and damage.

In 2022, Bonus Biogroup expanded its operations to a new, state-of-the-art facility designed to comply with Good Manufacturing Practice (GMP) standards. This facility, dedicated to the research and development and manufacturing of our products, is equipped to meet initial commercial demands. Housing two production halls and quality control labs, it is home to Israel's most advanced R&D labs for cell therapy and tissue engineering. In a testament to our continuous commitment to innovation, we established a bioinformatics unit in 2021, dedicated to researching and developing applications to augment the clinical and economic efficiency of cell therapies. In 2023, the Israeli Ministry of Health certified our facility and the MesenCure production process as GMP-compliant. In 2024, the company plans to initiate advanced-phase trials in the US for treating all-cause ARDS with MesenCure.

Bonus Biogroup has consistently demonstrated effective use of proceeds. With a total of $60M raised, we are bringing two leading products to Phase II completion in three distinct indications. On average, the company has raised private equity at a premium of 18% above the relevant closing share price, underscoring our commitment to protecting investors' equity. The company CEO and Executive Chairman continue to hold nearly half of its shares, reinforcing their control and commitment. In our most recent funding round, the company raised $11.5M based on a valuation of about half a billion USD.

Throughout the years, the company has formed collaborations with leading institutes worldwide, including MIT and Technion-Israel Institute of Technology. In the past three years alone, we have partnered with the Israel Institute for Biological Research, The Jackson Laboratory USA, and St. Catherine's Hospital in Zagreb, a world-leading center for personalized medicine. Among other, these partnerships aim to conduct advanced-stage clinical trials for Bonus Biogroup's technologies and products in Europe and the USA.

Bonus Biogroup's journey to the present day is a testament to its unwavering ambition and commitment to revolutionizing regenerative medicine. The company's patient-centric approach, scientific leadership, and technological innovation have led to the development of life-changing products. As we step into the future, Bonus Biogroup remains steadfast in its mission to empower millions worldwide to live healthier, longer lives, underscoring our belief that the best is yet to come.






MAIL ICON  info@bonus-bio.com

MAIL ICON  +972 (0)73 206 7104

MAIL ICONMatam Advanced Technology
Park P.O.B 15143 Haifa 31905 Israel

you tube linkedin facebook twitter

© 2022 Bonus BioGroup Ltd. Created By Netron Israel Ltd

Please publish modules in offcanvas position.